Q-omics provides the consensus-scored TMX2-CTNND1 profile across patient tissues and cancer cell-line models. TMX2-CTNND1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, TMX2-CTNND1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, TMX2-CTNND1 RNA expression shows 13,746 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, LUAD, and THYM as cancer lineages where TMX2-CTNND1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMX2-CTNND1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMX2-CTNND1 survival associations across molecular data types. TMX2-CTNND1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMX2-CTNND1 RNA expression–survival associations across cancer types. High TMX2-CTNND1 expression shows unfavorable associations in READ, ACC, CHOL and THCA, but favorable associations in UCS and SKCM. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for TMX2-CTNND1 RNA expression.
This table summarizes TMX2-CTNND1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMX2-CTNND1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMX2-CTNND1 shows lower tumor expression in LUAD, BRCA, READ, COAD, ESCA and LUSC. The LUAD box plot shows higher TMX2-CTNND1 RNA expression in normal versus tumor tissue (log2 FC = −0.141, t-test p < 0.001).
This table shows molecular features associated with TMX2-CTNND1 in patient tissues and cancer cell lines. In patient samples, TMX2-CTNND1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMX2-CTNND1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
